Lactose characteristics and the generation of the aerosol

Advanced Drug Delivery Reviews

Volumn 64, Issue 3, 2012, Pages 233-256

  Pilcer, Gabrielle ^a   Wauthoz, Nathalie ^a   Amighi, Karim ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Carrier; Characterisation; Dry powder inhaler; Inhalation; Particle interaction; Surface properties

Indexed keywords

ADHESIVE AND COHESIVE FORCES; AEROSOL GENERATION; CARRIER; CARRIER PARTICLES; CHARACTERISATION; DRUG FORMULATIONS; DRY POWDER INHALER; DRY POWDERS; INHALATION; INTERPARTICLE FORCE; PHYSICOCHEMICAL PROPERTY;

ATMOSPHERIC AEROSOLS; ATMOSPHERIC MOVEMENTS; DRUG PRODUCTS; PARTICLE INTERACTIONS; PARTICLE SIZE ANALYSIS; SURFACE PROPERTIES;

SUGARS;

BECLOMETASONE DIPROPIONATE; BECLOPHAR; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; LACTOSE; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; ZANAMIVIR;

AEROSOL; CARBOHYDRATE SYNTHESIS; CHEMICAL ANALYSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; DRY POWDER; FORCE; HUMAN; HUMIDITY; INHALATIONAL DRUG ADMINISTRATION; MOLECULAR INTERACTION; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY AIRFLOW; REVIEW; STATIC ELECTRICITY; SURFACE PROPERTY;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG CARRIERS; DRY POWDER INHALERS; LACTOSE;

EID: 84858624234     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.05.003     Document Type: Review

References (228)

1. Atkins P.J. Dry powder inhalers: an overview. Respir. Care 2005, 50:1304-1312.
2. Feeley J.C., York P., Sumby B.S., Dicks H. Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronisation. Int. J. Pharm. 1998, 172:89-96.
3. Hickey A.J. Pharmaceutical Inhalation Aerosol Technology 2004, Marcel Dekker, New York. second ed.
4. Steckel H., Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int. J. Pharm. 2004, 270:297-306.
5. Pilcer G., Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm. 2010, 392:1-19.
6. Larhrib H., Zeng X.M., Martin G.P., Marriott C., Pritchard J. The use of different grades of lactose as a carrier for aerosolised salbutamol sulphate. Int. J. Pharm. 1999, 191:1-14.
7. Zeng X.M., Pandhal K.H., Martin G.P. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int. J. Pharm. 2000, 197:41-52.
8. Flament M.P., Leterme P., Gayot A. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers. Int. J. Pharm. 2004, 275:201-209.
9. Zeng X.M., Martin G.P., Marriott C., Pritchard J. The effects of carrier size and morphology on the dispersion of salbutamol sulphate after aerosolization at different flow rates. J. Pharm. Pharmacol. 2000, 52:1211-1221.
10. Zeng X.M., Martin G.P., Marriott C., Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int. J. Pharm. 2000, 200:93-106.
11. Telko M.J., Hickey A.J. Dry powder inhaler formulation. Respir. Care 2005, 50:1209-1227.
12. Hinds W.C. Aerosol Technology: Properties, Behavior, and Measurement of Airbone Particles 1999, John Wiley & Sons, New York. second ed.
13. Alvarez C.A., Triplitt C. Advanced Drug Formulation Design to Optimize Therapeutic Outcomes 2008, Informa healthcare, New-York. R.O. Williams, D.R. Taft, J.T. McConville (Eds.).
14. Gonda I. Targeting by Deposition. Pharmaceutical Inhalation Aerosol Technology 2004, Marcel Dekker, New York. second ed. A.J. Hickey (Ed.).
15. European Pharmacopoeia November 15 2010, from, last accessed date. http://online.pheur.org/, 6.8th ed.
16. Karhu M., Kuikka J., Kauppinen T., Bergstrom K., Vidgren M. Pulmonary deposition of lactose carriers used in inhalation powders. Int. J. Pharm. 2000, 196:95-103.
17. Fowkes F. Attractive forces at interfaces. J India Eng Chem 1964, 56:40-52.
18. de Boer A.H., Hagedoorn P., Gjaltema D., Goede J., Frijlink H.W. Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int. J. Pharm. 2003, 260:187-200.
19. Visser J. An invited review Van der Waals and other cohesive forces affecting powder fluidization. Powder Technol. 1989, 58:1-10.
20. Butt H.J., Kappl M. Normal capillary forces. Adv. Colloid Interface Sci. 2009, 146:48-60.
21. Price R., Young P.M., Edge S., Staniforth J.N. The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. Int. J. Pharm. 2002, 246:47-59.
22. Matsusaka S., Maruyama H., Matsuyama T., Ghadiri M. Triboelectric charging of powders: a review. Chem. Eng. Sci. 2010, 65:5781-5807.
23. Bailey A.G. Charging of solids and powders. J. Electrostat. 1993, 30:167-180.
24. Elajnaf A., Carter P., Rowley G. Electrostatic characterisation of inhaled powders: effect of contact surface and relative humidity. Eur. J. Pharm. Sci. 2006, 29:375-384.
25. Bennett F.S., Carter P.A., Rowley G., Dandiker Y. Modification of electrostatic charge on inhaled carrier lactose particles by addition of fine particles. Drug Dev. Ind. Pharm. 1999, 25:99-103.
26. Murtomaa M., Harjunen P., Mellin V., Lehto V.P., Laine E. Effect of amorphicity on the triboelectrification of lactose powder. J. Electrostat. 2002, 56:103-110.
27. Murtomaa M., Mellin V., Harjunen P., Lankinen T., Laine E., Lehto V.P. Effect of particle morphology on the triboelectrification in dry powder inhalers. Int. J. Pharm. 2004, 282:107-114.
28. Bailey A.G., Hashish A.H., Williams T.J. Drug delivery by inhalation of charged particles. J. Electrostat. 1998, 44:3-10.
29. Chow K.T., Zhu K., Tan R.B., Heng P.W. Investigation of electrostatic behavior of a lactose carrier for dry powder inhalers. Pharm. Res. 2008, 25:2822-2834.
30. Telko M.J., Kujanpaa J., Hickey A.J. Investigation of triboelectric charging in dry powder inhalers using electrical low pressure impactor (ELPI). Int. J. Pharm. 2007, 336:352-360.
31. Hickey A.J., Mansour H.M., Telko M.J., Xu Z., Smyth H.D., Mulder T., McLean R., Langridge J., Papadopoulos D. Physical characterization of component particles included in dry powder inhalers. II. Dynamic characteristics. J. Pharm. Sci. 2007, 96:1302-1319.
32. Byron P.R., Peart J., Staniforth J.N. Aerosol electrostatics. I: properties of fine powders before and after aerosolization by dry powder inhalers. Pharm. Res. 1997, 14:698-705.
33. Young P.M., Sung A., Traini D., Kwok P., Chiou H., Chan H.K. Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems. Pharm. Res. 2007, 24:963-970.
34. Kawashima Y., Serigano T., Hino T., Yamamoto H., Takeuchi H. A new powder design method to improve inhalation efficiency of pranlukast hydrate dry powder aerosols by surface modification with hydroxypropylmethylcellulose phthalate nanospheres. Pharm. Res. 1998, 15:1748-1752.
35. Chew N.Y., Tang P., Chan H.K., Raper J.A. How much particle surface corrugation is sufficient to improve aerosol performance of powders ?. Pharm. Res. 2005, 22:148-152.
36. Adi H., Traini D., Chan H.K., Young P.M. The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. J. Pharm. Sci. 2008, 97:2780-2788.
37. Hooton J.C., Jones M.D., Harris H., Shur J., Price R. The influence of crystal habit on the prediction of dry powder inhalation formulation performance using the cohesive-adhesive force balance approach. Drug Dev. Ind. Pharm. 2008, 34:974-983.
38. Thielmann F., Burnett D.J., Heng J.Y. Determination of the surface energy distributions of different processed lactose. Drug Dev. Ind. Pharm. 2007, 33:1240-1253.
39. Zeng X.M., Martin G.P., Tee S.K., Ghoush A.A., Marriott C. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int. J. Pharm. 1999, 182:133-144.
40. Young P.M., Edge S., Traini D., Jones M.D., Price R., El-Sabawi D., Urry C., Smith C. The influence of dose on the performance of dry powder inhalation systems. Int. J. Pharm. 2005, 296:26-33.
41. Berard V., Lesniewska E., Andres C., Pertuy D., Laroche C., Pourcelot Y. Dry powder inhaler: influence of humidity on topology and adhesion studied by AFM. Int. J. Pharm. 2002, 232:213-224.
42. Das S., Larson I., Young P., Stewart P. Agglomerate properties and dispersibility changes of salmeterol xinofoate from powders for inhalation after storage at high relative humidity. Eur. J. Pharm. Sci. 2009, 37:442-450.
43. Das S., Larson I., Young P., Steward P. Surface energy changes and their relationship with the dispersibility of salmeterol xinofoate powders for inhalation after storage at high RH. Eur. J. Pharm. Sci. 2009, 38:347-354.
44. Watling C.P., Elliott J.A., Scruton C., Cameron R.E. Surface modification of lactose inhalation blends by moisture. Int. J. Pharm. 2010, 391:29-37.
45. Young P.M., Price R. The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. Eur. J. Pharm. Sci. 2004, 22:235-240.
46. Hickey A.J., Martonen T.B. Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives. Pharm. Res. 1993, 10:1-7.
47. Tuley R., Shrimpton J., Jones M.D., Price R., Palmer M., Prime D. Experimental observations of inhaler dry powder fluidisation. Int. J. Pharm. 2008, 358:238-247.
48. Weiler C., Egen M., Trunk M., Langguth P. Force control and powder dispersibility of spray dried particles for inhalation. J. Pharm. Sci. 2010, 99:303-316.
49. Xu Z., Mansour H.M., Mulder T., McLean R., Langridge J., Hickey A.J. Heterogeneous particle deaggregation and its implication for therapeutic aerosol performance. J. Pharm. Sci. 2010, 99:3442-3461.
50. Weiler C., Wolkenhauer M., Trunk M., Langguth P. New model describing the total dispersion of drug powder agglomerates. Powder Technol. 2010, 203:248-253.
51. de Boer A.H., Gjaltema D., Hagedoorn P., Schaller M., Witt W., Frijlink H.W. Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols. Int. J. Pharm. 2002, 249:233-245.
52. Dickhoff B.H., Ellison M.J., de Boer A.H., Frijlink H.W. The effect of budesonide particle mass on drug particle detachment from carrier crystals in adhesive mixtures during inhalation. Eur. J. Pharm. Biopharm. 2002, 54:245-248.
53. Edwards D.A., Li W. Aerosol particle transport and deaggregation phenomena in the mouth and throat. Adv. Drug Deliv. Rev. 1997, 26:41-49.
54. Sbirlea-Apiou G., Katz I., Caillibotte G., Martonen T., Yang Y. Deposition Mechanics of Pharmaceutical Particles in Human Airways. Inhalation Aerosols Physical and Biological Basis for Therapy 2007, 1-30. Informa heathcare, New York. second ed. A.J. Hickey (Ed.).
55. Musante C.J., Schroeter J.D., Rosati J.A., Crowder T.M., Hickey A.J., Martonen T.B. Factors affecting the deposition of inhaled porous drug particles. J. Pharm. Sci. 2002, 91:1590-1600.
56. De Boer A.H., Winter H.M., Lerk C.F.I. Inhalation characteristics and their effect on in vitro drug delivery from dry powder inhalers Part 1. Inhalation characteristics, work of breathing and volunteers' preference in dependence of the inhaler resistance. Int. J. Pharm. 1996, 130:231-244.
57. Martin G.P., MacRitchie H.B., Marriott C., Zeng X.M. Characterisation of a carrier-free dry powder aerosol formulation using inertial impaction and laser diffraction. Pharm. Res. 2006, 23:2210-2219.
58. Newman S.P., Busse W.W. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med. 2002, 96:293-304.
59. Coates M.S., Fletcher D.F., Chan H.K., Raper J.A. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: grid structure and mouthpiece length. J. Pharm. Sci. 2004, 93:2863-2876.
60. Voss A., Finlay W.H. Deagglomeration of dry powder pharmaceutical aerosols. Int. J. Pharm. 2002, 248:39-50.
61. Chan H.K. Dry powder aerosol delivery systems: current and future research directions. J. Aerosol Med. 2006, 19:21-27.
62. Dunbar C.A., Hickey A.J., Holzner P. Dispersion and characterization of pharmaceutical dry powder aerosols. Kona 1998, 16:7-45.
63. Srichana T., Martin G.P., Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm. Sci. 1998, 7:73-80.
64. Crowder T.M., Louey M.D., Sethuraman V.V., Smyth H.D.C., Hickey A.J. An odyssey in inhaler formulations and design. Pharm. Technol. 2001, 25(2001):99-113.
65. Tobyn M., Staniforth J.N., Morton D., Harmer Q., Newton M.E. Active and intelligent inhaler device development. Int. J. Pharm. 2004, 277:31-37.
66. Steckel H., Müller B.W. In vitro evaluation of dry powder inhalers. I. Drug deposition of commonly used devices. Int. J. Pharm. 1997, 154:19-29.
67. Islam N., Gladki E. Dry powder inhalers (DPIs) - a review of device reliability and innovation. Int. J. Pharm. 2008, 360:1-11.
68. Rowe R.C., Sheskey P.J., Owen S.C. Handbook of Pharmaceutical Excipients 2005, Pharmaceutical Press, London. fifth ed.
69. Edge S., Mueller S., Price R., Shur J. Factors affecting defining the quality and functionality of excipients used in the manufacture of dry powder inhaler products. Drug Dev. Ind. Pharm. 2008, 34:966-973.
70. Young P.M., Chan H.K., Chiou H., Edge S., Tee T.H., Traini D. The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J. Pharm. Sci. 2007, 96:1331-1341.
71. Chen B., Bautista R., Yu K., Zapata G.A., Mulkerrin M.G., Chamow S.M. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms. Pharm. Res. 2003, 20:1952-1960.
72. Elversson J., Millqvist-Fureby A., Alderborn G., Elofsson U. Droplet and particle size relationship and shell thickness of inhalable lactose particles during spray drying. J. Pharm. Sci. 2003, 92:900-910.
73. Sacchetti M., Van Oort M.M. Spray-drying and Supercritical Fluid Particle Generation Techniques. Inhalation Aerosols, Physical and Biological Basis for Therapy 1996, 337-384. Marcel Dekker, New York. A.J. Hickey (Ed.).
74. Harjunen P., Lehto V.P., Valisaari J., Lankinen T., Paronen P., Jarvinen K. Effects of ethanol to water ratio in feed solution on the crystallinity of spray-dried lactose. Drug Dev. Ind. Pharm. 2002, 28:949-955.
75. Johnson K.A. Preparation of peptide and protein powders for inhalation. Adv. Drug Deliv. Rev. 1997, 26:3-15.
76. Malcolmson R.J., Embleton J.K. Dry powder formulations for pulmonary delivery. PSTT 1998, 1:394-398.
77. Palakodaty S., York P., Pritchard J. Supercritical fluid processing of materials from aqueous solutions: the application of SEDS to lactose as a model substance. Pharm. Res. 1998, 15:1835-1843.
78. Bouchard A., Jovanovic N., Hofland G.W., Jiskoot W., Mendes E., Crommelin D.J., Witkamp G.J. Supercritical fluid drying of carbohydrates: selection of suitable excipients and process conditions. Eur. J. Pharm. Biopharm. 2008, 68:781-794.
79. Bustami R.T., Chan H.K., Sweeney T., Dehghani F., Foster N.R. Generation of fine powders of recombinant human deoxyribonuclease using the aerosol solvent extraction system. Pharm. Res. 2003, 20:2028-2035.
80. Allen T. Particle Size Measurement 1997, Chapman and Hall, London. fifth ed.
81. Staniforth J.N., Aulton M.E. Particle Size Separation. Aulton's Pharmaceutics: The Design and Manufacture of Medecines 2007, 145-151. Elsevier, Philadelphia. third ed. M.E. Aulton (Ed.).
82. Gotoh K., Masuda H., Higashitan K. Powder Technology Handbook 1997, Marcel Dekker, New York. second ed.
83. Adi H., Larson I., Chiou H., Young P., Traini D., Stewart P. Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation. Pharm. Res. 2006, 23:2556-2565.
84. Koushik K., Kompella U.B. Particle and device engineering for inhalation drug delivery. Drug Deliv. Technol. 2004, 4:40-50.
85. Zeng X.M., Martin G.P., Marriott C., Pritchard J. Crystallization of lactose from carbopol gels. Pharm. Res. 2000, 17:879-886.
86. Young P.M., Kwok P., Adi H., Chan H.K., Traini D. Lactose composite carriers for respiratory delivery. Pharm. Res. 2009, 26:802-810.
87. Kumon M., Suzuki M., Kusai A., Yonemochi E., Terada K. Novel approach to DPI carrier lactose with mechanofusion process with additives and evaluation by IGC. Chem. Pharm. Bull. 2006, 54:1508-1514.
88. Kumon M., Machida S., Suzuki M., Kusai A., Yonemochi E., Terada K. Application and mechanism of inhalation profile improvement of DPI formulations by mechanofusion with magnesium stearate. Chem. Pharm. Bull. 2008, 56:617-625.
89. Begat P., Morton D.A., Staniforth J.N., Price R. The cohesive-adhesive balances in dry powder inhaler formulations II: influence on fine particle delivery characteristics. Pharm. Res. 2004, 21:1826-1833.
90. El-Sabawi D., Price R., Edge S., Young P.M. Novel temperature controlled surface dissolution of excipient particles for carrier based dry powder inhaler formulations. Drug Dev. Ind. Pharm. 2006, 32:243-251.
91. Iida K., Hayakawa Y., Okamoto H., Danjo K., Leuenberger H. Preparation of dry powder inhalation by surface treatment of lactose carrier particles. Chem. Pharm. Bull. 2003, 51:1-5.
92. Iida K., Hayakawa Y., Okamoto H., Danjo K., Luenbergerb H. Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem. Pharm. Bull. 2003, 51:1455-1457.
93. Iida K., Todo H., Okamoto H., Danjo K., Leuenberger H. Preparation of dry powder inhalation with lactose carrier particles surface-coated using a Wurster fluidized bed. Chem. Pharm. Bull. 2005, 53:431-434.
94. Ferrari F., Cocconi D., Bettini R., Giordano F., Santi P., Tobyn M., Price R., Young P., Caramella C., Colombo P. The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer. AAPS PharmSciTech 2004, 5:1-6.
95. Young P.M., Cocconi D., Colombo P., Bettini R., Price R., Steele D.F., Tobyn M.J. Characterization of a surface modified dry powder inhalation carrier prepared by "particle smoothing". J. Pharm. Pharmacol. 2002, 54:1339-1344.
96. Sebti T., Vanderbist F., Amighi K. Evaluation of the content homogeneity and dispersion properties of fluticasone DPI compositions. J. Drug Deliv. Sci. Tech. 2007, 17:223-229.
97. Hersey J.A. Ordered mixing: a new concept in powder mixing practice. Powder Technol. 1975, 11:41-44.
98. Saleem I., Smyth H., Telko M. Prediction of dry powder inhaler formulation performance from surface energetics and blending dynamics. Drug Dev. Ind. Pharm. 2008, 34:1002-1010.
99. Poux R. Powder mixing: some practical rules applied to agitated systems. Powder Technol. 1991, 68:213-234.
100. Garcia T.P., Prescott J.K. Blending and Blend Uniformity. Pharmaceutical Dosage Forms: Tablets 2008, 111-174. Informa healthcare, New York. third ed. L.L. Augsburger, S.W. Hoag (Eds.).
101. Venables H.J., Wells J.I. Powder mixing. Drug Dev. Ind. Pharm. 2001, 27:599-612.
102. Jones M.D., Santo J.G., Yakub B., Dennison M., Master H., Buckton G. The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance. Int. J. Pharm. 2010, 391:137-147.
103. Clarck A.R. The use of laser diffraction for the evaluation of aerosol clouds generated by medical nebulizers. Int. J. Pharm. 1995, 115:69-78.
104. Bosquillon C., Lombry C., Preat V., Vanbever R. Comparison of particle sizing techniques in the case of inhalation dry powders. J. Pharm. Sci. 2001, 90:2032-2041.
105. de Boer A.H., Gjaltema D., Hagedoorn P., Frijnlink H.W. Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int. J. Pharm. 2002, 249:219-231.
106. Marriott C., MacRitchie H.B., Zeng X.M., Martin G.P. Development of a laser diffraction method for the determination of the particle size of aerolised powder formulations. Int. J. Pharm. 2006, 326:39-49.
107. Pilcer G., Vanderbist F., Amighi K. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. Int. J. Pharm. 2008, 358:75-81.
108. Motise P., Crabbs W., Lord T. Solid oral dosage forms: blend uniformity acceptance criteria. Hum. Drug CGMP Notes 1993, 1:5-6.
109. El-Hagrasy A.S., Morris H.R., D'Amico F., Lodder R.A., Drennen J.K. Near-infrared spectroscopy and imaging for the monitoring of powder blend homogeneity. J. Pharm. Sci. 2001, 90:1298-1307.
110. El-Hagrasy A.S., D'Amico F., Drennen J.K. A Process Analytical Technology approach to near-infrared process control of pharmaceutical powder blending. Part I: D-optimal design for characterization of powder mixing and preliminary spectral data evaluation. J. Pharm. Sci. 2006, 95:392-406.
111. El-Hagrasy A.S., Delgado-Lopez M., Drennen J.K. A Process Analytical Technology approach to near-infrared process control of pharmaceutical powder blending. Part II: qualitative near-infrared models for prediction of blend homogeneity. J. Pharm. Sci. 2006, 95:407-421.
112. El-Hagrasy A.S., Drennen J.K. A Process Analytical Technology approach to near-infrared process control of pharmaceutical powder blending. Part III: quantitative near-infrared calibration for prediction of blend homogeneity and characterization of powder mixing kinetics. J. Pharm. Sci. 2006, 95:422-434.
113. Hickey A.J., Mansour H.M., Telko M.J., Xu Z., Smyth H.D., Mulder T., McLean R., Langridge J., Papadopoulos D. Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J. Pharm. Sci. 2007, 96:1282-1301.
114. Brittain H.G. Overview of Physical Characterization Methodology. Physical Characterization of Pharmaceutical Solids 1995, 1-35. Marcel Dekker, New York. H.G. Brittain (Ed.).
115. Rodriguez-Spong B., Price C.P., Jayasankar A., Matzger A.J., Rodriguez-Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv. Drug Deliv. Rev. 2007, 56:241-274.
116. Shah B., Kakumanu V.K., Bansal A.K. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J. Pharm. Sci. 2006, 95:1641-1665.
117. Kontny M.J., Zografi G. Sorption of Water by Solids. Physical Characterization of Pharmaceutical Solids 1995, 387-418. Marcel Dekker, New York. H.G. Brittain (Ed.).
118. Concessio N.M., VanOort M.M., Knowles M.R., Hickey A.J. Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for pharmacodynamic effect. Pharm. Res. 1999, 16:828-834.
119. Lavoie F., Cartilier L., Thibert R. New methods characterizing avalanche behavior to determine powder flow. Pharm. Res. 2002, 19:887-893.
120. Carstensen J.T. Advanced Pharmaceutical Solids 2001, Marcel Dekker, New York.
121. Price R., Young P.M. Visualization of the crystallization of lactose from the amorphous state. J. Pharm. Sci. 2004, 93:155-164.
122. Steckel H., Markefka P., teWierik H., Kammelar R. Effect of milling and sieving on functionality of dry powder inhalation products. Int. J. Pharm. 2006, 309:51-59.
123. Adi S., Adi H., Chan H.K., Young P.M., Traini D., Yang R., Yu A. Scanning white-light interferometry as a novel technique to quantify the surface roughness of micron-sized particles for inhalation. Langmuir 2008, 24:11307-11312.
124. Murtomaa M., Strengell S., Laine E., Bailey A. Measurement of electrostatic charge of an aerosol using a grid-probe. J. Electrostat. 2003, 58:197-207.
125. Keskinen J., Pietarinen K., Lehtimaki M. Electrical low pressure impactor. J. Aerosol. Sci. 1992, 23:353-360.
126. Marjamaki M., Keskinen J., Chen D.R., Pui D.Y.H. Performance evaluation of the electrical low-pressure impactor (ELPI). J. Aerosol. Sci. 2000, 31:249-261.
127. Glover W., Chan H.K. Electrostatic charge characterization of pharmaceutical aerosols using electrical low-pressure impaction (ELPI). J. Aerosol. Sci. 2004, 35:755-764.
128. Hoe S., Traini D., Chan H.K., Young P.M. The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers. Pharm. Res. 2009, 26:2639-2646.
129. Hoe S., Traini D., Chan H.K., Young P.M. Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). Eur. J. Pharm. Sci. 2009, 38:88-94.
130. Saini D., Biris A.S., Srirama P.K., Mazumder M.K. Particle size and charge distribution analysis of pharmaceutical aerosols generated by inhalers. Pharm. Dev. Technol. 2007, 12:35-41.
131. Philip V.A., Mehta R.C., Mazumber M.K., DeLuca P.P. Effect of surface treatment on the respirable fractions of PLGA microspheres formulated for dry powder inhalers. Int. J. Pharm. 1997, 151:165-174.
132. Bunker M.J., Davies M.C., James M.B., Roberts C.J. Direct observation of single particle electrostatic charging by atomic force microscopy. Pharm. Res. 2007, 24:1165-1169.
133. Hancock B.C., Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997, 86:1-12.
134. Chen X., Bates S., Morris K.R. Quantifying amorphous content of lactose using parallel beam X-ray powder diffraction and whole pattern fitting. J. Pharm. Biomed. Anal. 2001, 26:63-72.
135. Katainen E., Niemela P., Harjunen P., Suhonen J., Jarvinen K. Evaluation of the amorphous content of lactose by solution calorimetry and Raman spectroscopy. Talanta 2005, 68:1-5.
136. Niemela P., Paallysaho M., Harjunen P., Koivisto M., Lehto V.P., Suhonen J., Jarvinen K. Quantitative analysis of amorphous content of lactose using CCD-Raman spectroscopy. J. Pharm. Biomed. Anal. 2005, 37:907-911.
137. Savolainen M., Jouppila K., Pajamo O., Christiansen L., Strachan C., Karjalainen M., Rantanen J. Determination of amorphous content in the pharmaceutical process environment. J. Pharm. Pharmacol. 2007, 59:161-170.
138. Whiteside P.T., Luk S.Y., Madden-Smith C.E., Turner P., Patel N., George M.W. Detection of low levels of amorphous lactose using H/D exchange and FT-Raman spectroscopy. Pharm. Res. 2008, 25:2650-2656.
139. Hogan S.E., Buckton G. The application of near infrared spectroscopy and dynamic vapor sorption to quantify low amorphous contents of crystalline lactose. Pharm. Res. 2001, 18:112-116.
140. Saunders M., Podluii K., Shergill S., Buckton G., Royall P. The potential of high speed DSC (hyper-DSC) for the detection and quantification of small amounts of amorphous content in predominantly crystalline samples. Int. J. Pharm. 2004, 274:35-40.
141. Buckton G. Surface characterization: understanding sources of variability in the production and use of pharmaceuticals. J. Pharm. Pharmacol. 1995, 47:265-275.
142. Kawakami K., Numa T., Ida Y. Assessment of amorphous content by microcalorimetry. J. Pharm. Sci. 2002, 91:417-423.
143. Hogan S.E., Buckton G. Water sorption/desorption-near IR and calorimetric study of crystalline and amorphous raffinose. Int. J. Pharm. 2001, 227:57-69.
144. Harjunen P., Lehto V.P., Koivisto M., Levonen E., Paronen P., Jarvinen K. Determination of amorphous content of lactose samples by solution calorimetry. Drug Dev. Ind. Pharm. 2004, 30:809-815.
145. Buckton G., Darcy P. Assessment of disorder in crystalline powders-a review of analytical techniques and their application. Int. J. Pharm. 1999, 179:141-158.
146. Burnett D.J. Determining the critical relative humidity for moisture-induced phase transitions. Int. J. Pharm. 2009, 287:123-133.
147. Vollenbroek J., Hebbink G.A., Ziffels S., Steckel H. Determination of low levels of amorphous content in inhalation grade lactose by moisture sorption isotherms. Int. J. Pharm. 2010, 395:62-70.
148. Young P.M., Chiou H., Tee T., Traini D., Chan H.K., Thielmann F., Burnett D. The use of organic vapor sorption to determine low levels of amorphous content in processed pharmaceutical powders. Drug Dev. Ind. Pharm. 2007, 33:91-97.
149. Van Oss R., Good R., Chaudhury M. Additive and nonadditive surface tension components and the interpretation of contact angles. Langmuir 1988, 4:884-891.
150. Buckton G. Characterisation of small changes in the physical properties of powders of significance for dry powder inhaler formulations. Adv. Drug Deliv. Rev. 1997, 26:17-27.
151. Schultz J., Lavielle L., Martin C. The role of the interface in carbon-fibre epoxy composites. J Adhes. 1987, 23:45-60.
152. Goss K.U. Considerations about the adsorption of organic molecules from the gas phase to surfaces: implications for inverse gas chromatography and the prediction of adsorption coefficients. J. Colloid Interface Sci. 1997, 190:241-249.
153. Mukhopadhyay P., Chakraborty S., Mukherjee S. Postcardiac injury rheumatism. J. Assoc. Physicians India 1995, 43:388-390.
154. Cline D., Dalby R. Predicting the quality of powders for inhalation from surface energy and area. Pharm. Res. 2002, 19:1274-1277.
155. Ticehurst M.D., York P., Rowe R.C., Dwivedi S.K. Characterisation of the surface properties of α-lactose monohydrate with inverse gas chromatography, used to detect batch variation. Int. J. Pharm. 1996, 141:93-99.
156. Newell H.E., Buckton G., Butler D.A., Thielmann F., Williams D.R. The use of inverse phase gas chromatography to measure the surface energy of crystalline, amorphous, and recently milled lactose. Pharm. Res. 2001, 18:662-666.
157. Traini D., Young P.M., Thielmann F., Acharya M. The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. Drug Dev. Ind. Pharm. 2008, 34:992-1001.
158. Planinsek O., Trojak A., Srcic S. The dispersive component of the surface free energy of powders assessed using inverse gas chromatography and contact angle measurements. Int. J. Pharm. 2001, 221:211-217.
159. Tong H.H., Shekunov B.Y., York P., Chow A.H. Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography. J. Pharm. Sci. 2006, 95:228-233.
160. Planinsek O., Zadnik J., Rozman S., Kunaver M., Dreu R., Srcic S. Influence of inverse gas chromatography measurement conditions on surface energy parameters of lactose monohydrate. Int. J. Pharm. 2003, 256:17-23.
161. Saxena A., Kendrick J., Grimsey I.M., Roberts R., York P. A combined modelling and experimental study of the surface energetics of alpha-lactose monohydrate. J. Pharm. Sci. 2010, 99:741-752.
162. Ho R., Muresan A.S., Hebbink G.A., Heng J.Y. Influence of fines on the surface energy heterogeneity of lactose for pulmonary drug delivery. Int. J. Pharm. 2010, 388:88-94.
163. Louey M.D., Mulvaney P., Stewart P.J. Characterisation of adhesional properties of lactose carriers using atomic force microscopy. J. Pharm. Biomed. Anal. 2001, 25:559-567.
164. Eve J.K., Patel N., Luk S.Y., Ebbens S.J., Roberts C.J. A study of single drug particle adhesion interactions using atomic force microscopy. Int. J. Pharm. 2002, 238:17-27.
165. Hooton J.C., German C.S., Allen S., Davies M.C., Roberts C.J., Tendler S.J., Williams P. Characterization of particle-interactions by atomic force microscopy: effect of contact area. Pharm. Res. 2003, 20:508-514.
166. Traini D., Young P.M., Jones M., Edge S., Price R. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation. Eur. J. Pharm. Sci. 2006, 27:243-251.
167. Berard V., Lesniewska E., Andres C., Pertuy D., Laroche C., Pourcelot Y. Affinity scale between a carrier and a drug in DPI studied by atomic force microscopy. Int. J. Pharm. 2002, 247:127-137.
168. Islam N., Stewart P., Larson I., Hartley P. Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?. Pharm. Res. 2004, 21:492-499.
169. Louey M.D., Stewart P.J. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharm. Res. 2002, 19:1524-1531.
170. Adi H., Larson I., Stewart P.J. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation. Int. J. Pharm. 2007, 337:229-238.
171. Islam N., Stewart P., Larson I., Hartley P. Surface roughness contribution to the adhesion force distribution of salmeterol xinafoate on lactose carriers by atomic force microscopy. J. Pharm. Sci. 2005, 94:1500-1511.
172. Begat P., Morton D.A., Staniforth J.N., Price R. The cohesive-adhesive balances in dry powder inhaler formulations I: direct quantification by atomic force microscopy. Pharm. Res. 2004, 21:1591-1597.
173. Podczeck F., Newton J.M. Development of an ultracentrifuge technique to determine the adhesion and friction properties between particles and surfaces. J. Pharm. Sci. 1995, 84:1067-1071.
174. Shimada Y., Sunada M., Mizuno M., Yonezawa Y., Sunada H., Yokosuka M., Kimura H., Takebayashi H. Measurement of the adhesive force of fine particles on tablet surfaces and method of their removal. Drug Dev. Ind. Pharm. 2000, 26:149-158.
175. Nguyen T.T., Rambanapasi C., de Boer A.H., Frijlink H.W., Ven P.M., de Vries J., Busscher H.J., Maarschalk K.D. A centrifuge method to measure particle cohesion forces to substrate surfaces: the use of a force distribution concept for data interpretation. Int. J. Pharm. 2010, 393:88-95.
176. Thi T.H., Danede F., Descamps M., Flament M.P. Comparison of physical and inhalation properties of spray-dried and micronized terbutaline sulphate. Eur. J. Pharm. Biopharm. 2008, 70:380-388.
177. Louey M.D., Razia S., Stewart P.J. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures. Int. J. Pharm. 2003, 252:87-98.
178. Jones M.D., Price R. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm. Res. 2006, 23:1665-1674.
179. Smyth H.D., Hickey A.J. Carriers in drug powder delivery: implications for inhalation system design. Am. J. Drug Deliv. 2005, 3:117-132.
180. Baldrick P., Bamford D.G. A toxicological review of lactose to support clinical administration by inhalation. Food Chem. Toxicol. 1997, 35:719-733.
181. Clark B., Moss G., Ritchie J. The fate of [14C] lactose administered into the lungs of rats and monkeys. J. Pharm. Pharmacol. 1974, 28:818-820.
182. Pitchayajittipong C., Price R., Shur J., Kaerger J.S., Edge S. Characterisation and functionality of inhalation anhydrous lactose. Int. J. Pharm. 2010, 390:134-141.
183. Wong D.Y.T., Wright P., Aulton M.E. The deformation of alpha-lactose monohydrate and anhydrous alpha-lactose monocrystals. Drug Dev. Ind. Pharm. 1988, 2109-2126.
184. French D.L., Edwards D.A., Niven R.W. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol. Sci. 1996, 27:769-783.
185. Steckel H., Brandes H.G. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int. J. Pharm. 2004, 278:187-195.
186. Dickhoff B.H., de Boer A.H., Lambregts D., Frijlink H.W. The effect of carrier surface and bulk properties on drug particle detachment from crystalline lactose carrier particles during inhalation, as function of carrier payload and mixing time. Eur. J. Pharm. Biopharm. 2003, 56:291-302.
187. Bell J.H., Hartley P.S., Cox J.S. Dry powder aerosols. I. A new powder inhalation device. J. Pharm. Sci. 1971, 60:1559-1564.
188. Ganderton D., Kassem N.M. Dry Powder Inhalers. Advances in Pharmaceutical Sciences 1992, 165-191. Academic Press, London. D. Ganderton, T.E. Jones (Eds.).
189. Zeng X.M., Martin G.P., Marriott C., Pritchard J. The influence of crystallization conditions on the morphology of lactose intended for use as a carrier for dry powder aerosols. J. Pharm. Pharmacol. 2000, 52:633-643.
190. Zeng X.M., Martin G.P., Tee S.K., Marriott C. The role of fine particle lactose on the dispersion and deaggragation of salbutamol sulphate in an air stream in vitro. Int. J. Pharm. 1998, 176:99-110.
191. Lucas P., Anderson K., Staniforth J.N. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm. Res. 1998, 15:562-569.
192. Adi H., Larson I., Stewart P. Influence of Particle Size of the Fine Lactose in the Dispersion of Salmeterol Xinafoate from Lactose Mixtures for Inhalation. Respiratory Drug Delivery IX 2004, 553-556. Davis Healthcare International, Palm Desert, California. R.N. Dalby (Ed.).
193. Handoko A., Ian L., Peter S.J. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation. Eur. J. Pharm. Sci. 2009, 36:265-274.
194. Guenette E., Barrett A., Kraus D., Brody R., Harding L., Magee G. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. Int. J. Pharm. 2009, 380:80-88.
195. Guchardi R., Frei M., John E., Kaerger J.S. Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations. Int. J. Pharm. 2008, 348:10-17.
196. Islam N., Stewart P., Larson I., Hartley P. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures. J. Pharm. Sci. 2004, 93:1030-1038.
197. Zeng X.M., Martin G.P., Marriott C., Pritchard J. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. J. Pharm. Sci. 2001, 90:1424-1434.
198. Adi H., Larson I., Chiou H., Young P., Traini D., Stewart P. Role of agglomeration in the dispersion of salmeterol xinafoate from mixtures for inhalation with differing drug to fine lactose ratios. J. Pharm. Sci. 2008, 97:3140-3152.
199. Jones M.D., Harris H., Hooton J.C., Shur J., King G.S., Mathoulin C.A., Nichol K., Smith T.L., Dawson M.L., Ferrie A.R., Price R. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances. Eur. J. Pharm. Biopharm. 2008, 69:496-507.
200. Andya J.D., Maa Y.F., Costantino H.R., Nguyen P.A., Dasovich N., Sweeney T.D., Hsu C.C., Shire S.J. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm. Res. 1999, 16:350-358.
201. Lo Y.L., Tsai J.C., Kuo J.H. Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase. J. Control. Release 2004, 94:259-272.
202. You Y., Zhao M., Liu G., Tang X. Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method. J. Pharm. Pharmacol. 2007, 59:927-934.
203. Gao J., Ding X., Chu C., Lu L., Zhang Y., Chen Y., Fan W., Li G., Gao S. Dry powder inhalations containing thymopentin and its immunomodulating effects in Wistar rats. Eur. J. Pharm. Sci. 2009, 36:572-579.
204. Wang L., Zhang Y., Tang X. Characterization of a new inhalable thymopentin formulation. Int. J. Pharm. 2009, 375:1-7.
205. Jensen D.M., Cun D., Maltesen M.J., Frokjaer S., Nielsen H.M., Foged C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J. Control. Release 2010, 142:138-145.
206. Bosquillon C., Lombry C., Preat V., Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J. Control. Release 2001, 70:329-339.
207. Vanbever R., Mintzes J.D., Wang J., Nice J., Chen D., Batycky R., Langer R., Edwards D.A. Formulation and physical characterization of large porous particles for inhalation. Pharm. Res. 1999, 16:1735-1742.
208. Codrons V., Vanderbist F., Verbeeck R.K., Arras M., Lison D., Preat V., Vanbever R. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J. Pharm. Sci. 2003, 92:938-950.
209. Bosquillon C., Rouxhet P.G., Ahimou F., Simon D., Culot C., Preat V., Vanbever R. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release 2004, 99:357-367.
210. Tsifansky M.D., Yeo Y., Evgenov O.V., Bellas E., Benjamin J., Kohane D.S. Microparticles for inhalational delivery of antipseudomonal antibiotics. AAPS J. 2008, 10:254-260.
211. Yang Y., Tsifansky M.D., Wu C.J., Yang H.I., Schmidt G., Yeo Y. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm. Res. 2010, 27:151-160.
212. Grenha A., Seijo B., Remunan-Lopez C. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur. J. Pharm. Sci. 2005, 25:427-437.
213. Chougule M., Padhi B., Misra A. Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. Int. J. Nanomedicine 2007, 2:675-688.
214. Tomoda K., Ohkoshi T., Kawai Y., Nishiwaki M., Nakajima T., Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Colloids Surf. B Biointerfaces 2008, 61:138-144.
215. Huang W.H., Yang Z.J., Wu H., Wong Y.F., Zhao Z.Z., Liu L. Development of liposomal salbutamol sulfate dry powder inhaler formulation. Biol. Pharm. Bull. 2010, 33:512-517.
216. Tee S.K., Marriott C., Zeng X.M., Martin G.P. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int. J. Pharm. 2000, 208:111-123.
217. Stahl K., Backstorm K., Thalberg K., Axelsson A., Schaefer T., Kristensen H.G. Spray drying and characterization of particles for inhalation. Respir. Dev. Drug 2002, 8:565-568.
218. Mao J., Blair J. Effect of additives on the aerosolization properties of spray dried trehalose powders. Respir. Deliv. Drug 2004, 9:653-656.
219. Glover W., Chan H.K., Eberl S., Daviskas E., Verschuer J. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. Int. J. Pharm. 2008, 349:314-322.
220. Seville P.C., Li H.Y., Learoyd T.P. Spray-dried powders for pulmonary drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 2007, 24:307-360.
221. Lechuga-Ballesteros D., Charan C., Stults C.L., Stevenson C.L., Miller D.P., Vehring R., Tep V., Kuo M.C. Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J. Pharm. Sci. 2008, 97:287-302.
222. Sebti T., Amighi K. Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation. Eur. J. Pharm. Biopharm. 2006, 63:51-58.
223. Pilcer G., Sebti T., Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm. Res. 2006, 23:931-940.
224. Pilcer G., Vanderbist F., Amighi K. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties. J. Pharm. Sci. 2009, 98:1463-1475.
225. Iida K., Inagaki Y., Todo H., Okamoto H., Danjo K., Luenberger H. Effects of surface processing of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem. Pharm. Bull. 2004, 52:938-942.
226. El-Sabawi D., Edge S., Price R., Young P.M. Continued investigation into the influence of loaded dose on the performance of dry powder inhalers: surface smoothing effects. Drug Dev. Ind. Pharm. 2006, 32:1135-1138.
227. Iida K., Hayakawa Y., Okamoto H., Danjo K., Luenberger H. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem. Pharm. Bull. 2004, 52:350-353.
228. Zeng X.M., Martin G.P., Marriott C., Pritchard J. The use of lactose recrystallised from carbopol gels as a carrier for aerolised salbutamol sulphate. Eur. J. Pharm. Biopharm. 2001, 51:55-62.